MAPT and Alzheimer disease: GLP1 analogs, TZDs, SGLT2 inhibitors, DPP4 inhibitors, SU and insulin show overall benefits for amyloid and tau pathologies, neuron health, inflammatory and vascular alterations, alongside improved cognition in animal models mimicking AD and/or diabetes.